Top news of the week: 08.12.2020.
Companies And Industries
Arena Pharma's R&D lead quits 6 months into the job, replaced by Alder CMO
In the summer, Arena Pharmaceuticals hired Chris Cabell, M.D., as its chief medical officer, senior vice president and head of R&D, but now he’s out the door.
The Dish’s Weekly Biotechnology News Wrap Up – December 4, 2020
*|RSSFEED:DATE|* Incase you missed it. We summarized the week's top biotechnology stories.
Latin America: How pharma can navigate a complex market
Bureaucracy, political upheaval, and lack of regulations continue to make Latin America a difficult market for European and North American pharma to enter – and COVID-19 has only worsened ...
Brooks Automation Acquires Biospecimen Procurement CRO Trans-Hit Biomarkers
Brooks Automation, Inc. just announced that it has acquired Trans-Hit Biomarkers Inc. (THB), a worldwide biospecimen procurement service provider based in Montreal Canada. THB has an ...
Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer
Sutro Biopharma’s lead antibody-drug conjugate beat back ovarian cancer in a small phase 1 study, shrinking tumors in 13% of patients who had tried a median of six other treatments ...
Amgen, Takeda and UCB join forces in new COVID-19 drug repurposing study
Even as the FDA has already approved or authorized several COVID-19 drugs, there's still plenty of room for better therapies for a broad variety of patients. Now, three pharma companies ...
Ovid flunks Angelman phase 3, leaving field wide open for rivals
A phase 3 trial of Ovid Therapeutics’ OV101 in Angelman syndrome has missed its primary endpoint, sending the biotech’s stock down 50%. Ovid has paused most other elements of its OV101 ...
Covid-19 Pandemic Drives RNA Therapeutics into the Mainstream
With messenger RNA being pushed to the market in record time and Alnylam’s historic approval of an RNA interference drug, the field of RNA therapeutics is now moving faster than ever ...